| Authors: |
Belbezier A; Sorbonne Université, INSERM, Immunology-Immunopathology-Immunotherapy (i3), Paris, France., Engeroff P; Sorbonne Université, INSERM, Immunology-Immunopathology-Immunotherapy (i3), Paris, France., Fourcade G; Sorbonne Université, INSERM, Immunology-Immunopathology-Immunotherapy (i3), Paris, France., Vantomme H; Sorbonne Université, INSERM, Immunology-Immunopathology-Immunotherapy (i3), Paris, France., Vaineau R; Sorbonne Université, INSERM, Immunology-Immunopathology-Immunotherapy (i3), Paris, France., Gouritin B; Sorbonne Université, INSERM, Immunology-Immunopathology-Immunotherapy (i3), Paris, France., Bellier B; Sorbonne Université, INSERM, Immunology-Immunopathology-Immunotherapy (i3), Paris, France.; Assistance Publique - Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Biotherapy (CIC-BTi) and Inflammation-Immunopathology-Biotherapy Department (i2B), Paris, France., Brocheriou I; Assistance Publique - Hôpitaux de Pari (AP-HP), Hôpital Pitié-Salpêtrière, Department of Pathology, Paris, France., Tchitchek N; Sorbonne Université, INSERM, Immunology-Immunopathology-Immunotherapy (i3), Paris, France., Graff-Dubois S; Sorbonne Université, INSERM, Immunology-Immunopathology-Immunotherapy (i3), Paris, France., Klatzmann D; Sorbonne Université, INSERM, Immunology-Immunopathology-Immunotherapy (i3), Paris, France.; Assistance Publique - Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Biotherapy (CIC-BTi) and Inflammation-Immunopathology-Biotherapy Department (i2B), Paris, France. |
